Novel therapies in development: 4 reports

 

REPORT FROM ECTRIMS – BARCELONA, SPAIN – OCTOBER 7-10, 2015 – A number of novel therapies that target inflammation and/or neurodegeneration in MS are currently being investigated. Among them is MEDI-551, a B-cell directed monoclonal antibody that depletes CD19+ B cells. Unlike CD20+ (targeted by ocrelizumab and ofatumumab), CD19+ is expressed throughout B cell maturation, from pro-B cells to early plasma cell stages.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page